Identification and validation of an immune-derived multiple programmed cell death index for predicting clinical outcomes, molecular subtyping, and drug sensitivity in lung adenocarcinoma.

Chunhong LiJiahua HuXiling JiangHaiyin TanYiming Mao

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)

Therefore, MPCDI can be used as a novel clinical diagnostic classifier, providing valuable insights into the clinical management and clinical decision-making for LUAD patients.

Keyphrases

end stage renal disease
decision making
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
single molecule
patient reported outcomes
drug induced